Amy M. Pearlman, MD, highlights 6 studies in sexual dysfunction and infertility being presented at the 2022 American Urological Association Annual Meeting.
In this video, Amy M. Pearlman, MD, discusses 6 studies in sexual dysfunction and infertility being presented at the 2022 American Urological Association Annual Meeting. Pearlman is a clinical assistant professor and Men's Health Program Director at the University of Iowa, Iowa City.
The following 6 abstracts are previewed:
LBA02-09 (Hallak, et al): Intracellular SARS-COV-2 Found In The Spermatozoa Of Convalescent Men With Negative Pcr Semen Samples Revealed By Electron Microscopy
LBA02-11 (Shechter, et al): Novel On-Demand Treatment For Lifelong Premature Ejaculation Using Transcutaneous Perineal Mini-Patch Stimulator
PD09-05 (Marinaro, et al): Use of Fresh Ejaculated Semen Samples on the Day of Planned mTESE in Men with "Azoospermia"
MP21-02 (Flores, et al): Predictors of Corporo-Venocclusive Dysfunction (CVOD) in Men With Bilateral Nerve-Sparing Radical Prostatectomy (RP)
PD23-01 (Tyler, et al): Improved Peyronie's Disease Curvature Outcomes Using a More Aggressive Collagenase Technique
MP34-02 (Able, et al): Opioid Prescribing Following Male Infertility Surgery is Associated with Persistent Opioid Use - Analysis of a U.S. Claims Database
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.